I-125 radioactive seed

I-125 radioactive seed

Radiation oncology A small radioactive seed implanted into the prostate under ultrasound guidance for treating prostate CA–brachytherapy. See Ultrasound-guided transperineal permanent palladium-103 implantation of prostate.
References in periodicals archive ?
The Company seeks to market a portfolio of products including its two main proprietary products for the treatment of prostate cancer: the CaverMap Surgical Aid, available to aid physicians in preserving vital nerves during prostate cancer surgery, and the Symmetra I-125 radioactive seed used in brachytherapy procedures to treat localized prostate cancer.
Contract award: Brachytherapy I-125 Radioactive Seeds and Consumables.
WS), which develops products for the radiation oncology, interventional cardiology, and orthopedic marketplaces, today announced that it has received CE Mark approval to market its I-Plant(TM) Iodine I-125 radioactive seeds in Europe for the treatment of prostate cancer.
ALLIANT has combined the businesses of UroMed Corporation and SSGI/Prowess and the new company markets a portfolio of products including: the Symmetra I-125 radioactive seeds, used in brachytherapy procedures to treat localized prostate cancer; brachytherapy implant needles; Prowess 3D Treatment Planning Software including Prowess 3D for external beam cancer treatment; and BrachyPro, the Prowess 3D brachytherapy treatment planning system.
Supply I-125 radioactive seeds for prostate and eye for Radiation Oncology Department of Health Valencia La Fe brachytherapy.
ALLIANT has combined the businesses of UroMed and SSGI/Prowess and the new company markets a portfolio of products including: the Symmetra I-125 radioactive seeds, used in brachytherapy procedures to treat localized prostate cancer; brachytherapy implant needles; Prowess 3D Treatment Planning Software including Prowess 3D for external beam cancer treatment; and BrachyPro, the Prowess 3D brachytherapy treatment planning system.
Supply I-125 radioactive seeds for brachytherapy and ophthalmic for Radiation Oncology Service, Department of Health Valencia - La Fe
The Company recognizes that the previous paragraphs contain forward-looking statements relating to the Company's future activities, including the benefits expected through the Company's combination with SSGI, the development and commercialization of the SSGI product line and the company's CaverMap Surgical Aid and Symmetra I-125 radioactive seeds, the Company's anticipated sequential improvement in operating performance in the first quarter of 2001 and future growth.
Contract notice: Supply I-125 radioactive seeds for brachytherapy and ophthalmic for Radiation Oncology Service, Department of Health Valencia - La Fe
As a result of the combination of the business of UroMed and SSGI, the new company will seek to market a portfolio of products including: the Symmetra I-125 radioactive seeds, used in brachytherapy procedures to treat localized prostate cancer, the CaverMap Surgical Aid, available to aid physicians in preserving vital nerves during prostate cancer surgery; brachytherapy introducer needles; Prosim - SSGI/Prowess product platform for 3D external beam cancer treatment, and the BrachyPro - SSGI/Prowess brachytherapy treatment planning system.
As a result of the combination of the business of UroMed and SSGI, the new company will seek to market a portfolio of products including: the CaverMap Surgical Aid, available to aid physicians in preserving vital nerves during prostate cancer surgery; the Symmetra I-125 radioactive seeds, used in brachytherapy procedures to treat localized prostate cancer; brachytherapy introducer needles; Prosim - SSGI/Prowess product platform for 3D external beam cancer treatment, and the BrachyPro - SSGI/Prowess brachytherapy treatment planning system.
The Company seeks to market a portfolio of products including its two main proprietary products for the treatment of prostate cancer: the CaverMap(R) Surgical Aid, available to aid physicians in preserving vital nerves during prostate cancer surgery, and the Symmetra(TM) I-125 radioactive seeds, used in brachytherapy procedures to treat localized prostate cancer.